Tic
disorder is a
type of mental disorder, characterized by sudden and nonrhythmic movements.
According to the World Health Organisation (WHO), this disease can be
categorized into five types; transient, combined vocal and multiple motor,
unspecified, and chronic motor tic disorder.
Some of the symptoms
of the disease are facial grimacing, excessive blinking, uncontrollable
movements of the legs, and sound such as throat clearing. Majorly found in
children, this disease can be treated by a combination therapy of drugs, that
reduce the dopamine concentration in the brain.
Request
to Get Free Sample Pages at:
However,
cognitive behavioural therapy is also being used for the treatment of this
disease. Abide Therapeutics Inc. is in the process of developing ABX-1431 for
the treatment of tic disorder. Neurocrine Biosciences is in the process of
developing valbenazine as a vesicular monoamine transporter 2 inhibitor for the
treatment of this disorder.
Make
Enquiry Before Buying the Report:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
